On this page
⚠ Educational content only Not medical or genetic advice. Speak with a healthcare provider or genetic counsellor before acting on anything here.
Endocrine

Familial hypocalciuric hypercalcaemia

FHH is typically a mild, lifelong condition present from birth, affecting calcium regulation. It is often discovered incidentally during routine blood tests and usually does not require specific treatment, though some people may experience mild symptoms.

Autosomal dominant Endocrine OMIM:145980
1:78,000
Prevalence
Population estimate
50%
Inheritance
Autosomal dominant - each child of a parent who has the variant has a 50% chance of inheriting it
1
Associated genes
CASR

Available at Jeen Health

Clinical tests that include this

Overview

Familial hypocalciuric hypercalcaemia (FHH) is a rare inherited disorder that affects the body's ability to regulate calcium. People with FHH consistently have higher-than-normal levels of calcium in their blood, alongside lower-than-normal levels of calcium in their urine. Unlike some other causes of high blood calcium, FHH is generally a benign condition that does not usually lead to serious health problems and often requires no specific treatment [PMID:33671217]. It is typically discovered incidentally when blood tests are performed for other reasons.

FHH is distinct from primary hyperparathyroidism, another condition that can cause high blood calcium. Distinguishing between these two conditions is important because their management approaches are different. FHH is a lifelong condition present from birth, though it may not be identified until adulthood.

FHH affects approximately 1 in 78,000 individuals, but the exact prevalence may be underestimated as many people remain asymptomatic and undiagnosed.

Symptoms & clinical features

Many individuals with FHH do not experience any noticeable symptoms, and the condition is often found during routine blood tests. When symptoms do occur, they are typically mild and non-specific. These can include fatigue, increased thirst, and frequent urination [PMID:33671217].

Unlike primary hyperparathyroidism, FHH rarely causes severe complications such as kidney stones or bone problems. In some cases, high blood calcium levels can contribute to feelings of tiredness or weakness. However, these symptoms are often subtle and may not be directly attributed to the condition by the individual themselves.

Video: Genetics 101

Affected organs

FHH primarily affects the parathyroid glands and the kidneys. The parathyroid glands are four small glands located in the neck, close to the thyroid gland, which produce parathyroid hormone (PTH). PTH plays a crucial role in regulating calcium levels in the blood.

The kidneys are also central to calcium balance. They filter blood and help to either reabsorb calcium back into the bloodstream or excrete it in the urine. In FHH, there is an altered response to calcium in both the parathyroid glands and the kidneys, leading to the characteristic high blood calcium and low urine calcium levels.

Multiple body systems
Multiple body systems
Systemic involvement
Cellular impact
Cellular impact
Mechanism at cellular level

Risks & severity

FHH is generally considered a benign condition with a favourable prognosis, meaning it typically does not lead to severe health complications. The severity of symptoms, if present, is usually mild. Most individuals with FHH have a normal life expectancy and do not develop the serious complications often associated with other causes of chronic hypercalcaemia, such as significant kidney damage or bone demineralisation.

There is a very rare, more severe form of FHH known as neonatal severe hyperparathyroidism (NSHPT), which occurs when a baby inherits two copies of the altered gene (one from each parent). NSHPT presents shortly after birth with profoundly high calcium levels, severe bone demineralisation, and can be life-threatening if not promptly treated [PMID:20301646]. However, this is an extremely rare occurrence, and the typical form of FHH (inherited from one parent) is usually mild.

Genetic causes

Familial hypocalciuric hypercalcaemia is most commonly caused by pathogenic variants in the CASR gene. The CASR gene provides instructions for making a protein called the calcium-sensing receptor. This receptor acts like a sensor, primarily in the parathyroid glands and kidneys, to detect changes in blood calcium levels [PMID:33671217].

When blood calcium levels are high, the calcium-sensing receptor normally signals the parathyroid glands to reduce parathyroid hormone production, and the kidneys to excrete more calcium. In FHH, a variant in the CASR gene causes the receptor to become less sensitive to calcium. This 'faulty' receptor causes the body to incorrectly perceive calcium levels as being too low, even when they are normal or high. As a result, the parathyroid glands continue to release parathyroid hormone, and the kidneys reabsorb too much calcium, leading to persistently elevated blood calcium and reduced calcium excretion in the urine.

  • CASR
    calcium sensing receptor
    The CASR gene encodes the calcium-sensing receptor, a protein crucial for monitoring and regulating calcium levels in the blood and maintaining mineral homeostasis.

Inheritance pattern

Familial hypocalciuric hypercalcaemia follows an autosomal dominant pattern of inheritance. This means that a person only needs to inherit one altered copy of the CASR gene from one parent to develop the condition. Each child of an affected parent has a 50% chance of inheriting the altered gene and therefore developing FHH.

FHH affects males and females equally. Since the condition is often mild or asymptomatic, a parent with FHH may not be aware they have the condition until it is identified in themselves or a child. The rare, more severe form, neonatal severe hyperparathyroidism, occurs when a child inherits an altered CASR gene from both parents, which follows an autosomal recessive pattern for that severe presentation.

♀ Affected parent 1 altered copy ♂ Unaffected parent 2 typical copies Affected Unaffected Unaffected Affected Affected Carrier Unaffected Circles = females · Squares = males

Each child of an affected parent has a 50% chance of inheriting the pathogenic variant, regardless of sex.

Diagnosis & testing

Diagnosing FHH typically begins with routine blood tests showing persistently elevated blood calcium levels. Further testing to distinguish FHH from other causes of hypercalcaemia includes measuring parathyroid hormone (PTH) levels, which are often normal or mildly elevated in FHH, and a 24-hour urine collection to assess calcium excretion, which will show low levels of calcium in the urine relative to the blood calcium levels.

Genetic testing for variants in the CASR gene confirms the diagnosis. Referral to a clinical genetics service is part of the NHS Genomic Medicine Service pathway (relevant R-code: R355 Familial hypocalcaemic hypercalcaemia) for genetic testing. This is usually initiated following a referral from an endocrinologist or general practitioner. A genetic counsellor can provide support and information throughout the diagnostic process.

Management & lifestyle

For most individuals with FHH, specific medical treatment is not usually required because the condition is generally benign and does not cause significant health problems. It is important to confirm the diagnosis accurately to avoid unnecessary surgery (parathyroidectomy) that might be performed for other causes of hypercalcaemia, as this surgery is generally ineffective for FHH.

Management typically involves regular monitoring of calcium levels and supportive care for any mild symptoms. Individuals are usually encouraged to maintain good hydration. Genetic counselling can be helpful for affected individuals and their families to understand the condition, its inheritance pattern, and implications for relatives. There are no specific medications that directly treat the underlying genetic cause of FHH, and management focuses on observation and symptom control if needed.

UK care pathway

In the UK, suspected cases of FHH are typically managed through a clear care pathway within the NHS. This usually involves initial assessment by a GP, followed by referral to an endocrinologist for further investigation of hypercalcaemia. If FHH is suspected, a referral to a clinical genetics service can be made for diagnostic genetic testing (R-code R355). Genetic counsellors play a vital role, offering information, support, and guidance on inheritance and family implications as part of the NHS Genomic Medicine Service.

Frequently asked questions

Is FHH a serious condition?

No, FHH is generally a mild and benign condition. Most people with FHH do not experience significant health problems or symptoms, and it does not typically affect life expectancy. However, very rarely, a severe form can occur in infants who inherit two copies of the altered gene.

Do I need treatment for FHH?

Most individuals with FHH do not require specific medical treatment. The best approach is usually regular monitoring of calcium levels, and management focuses on supportive care for any mild symptoms that may arise. Surgery is generally not effective for FHH and is usually not recommended.

How did I get FHH, and can I pass it on?

FHH is an inherited condition that follows an autosomal dominant pattern. This means you inherited one altered copy of the CASR gene from one of your parents. Each of your children would have a 50% chance of inheriting the altered gene and therefore developing FHH.

How is FHH diagnosed?

Diagnosis involves blood tests showing high calcium and sometimes normal or mildly high parathyroid hormone levels, along with a 24-hour urine test showing low calcium excretion. The diagnosis is confirmed by genetic testing to identify a variant in the CASR gene.

What is the difference between FHH and primary hyperparathyroidism?

Both conditions cause high blood calcium, but FHH is due to an altered calcium-sensing receptor, resulting in low urine calcium. Primary hyperparathyroidism, usually caused by a tumour of a parathyroid gland, typically results in high parathyroid hormone and normal or high urine calcium. Distinguishing them is crucial for appropriate management.

References

  1. Mifsud S, Cilia K, Mifsud EL. Lithium-associated hyperparathyroidism. British journal of hospital medicine (London, England : 2005). 2020. PMID: 33263481
  2. Hannan FM, Kallay E, Chang W. The calcium-sensing receptor in physiology and in calcitropic and noncalcitropic diseases. Nature reviews. Endocrinology. 2018. PMID: 30443043
  3. Familial hypocalciuric hypercalcaemia. Lancet (London, England). 1982. PMID: 6121146
  4. Paterson CR, Gunn A. Familial benign hypercalcaemia. Lancet (London, England). 1981. PMID: 6113439
  5. Kristiansen JH. Familial hypocalciuric hypercalcaemia. Danish medical bulletin. 1992. PMID: 1526184
  6. Duan K, Gomez Hernandez K, Mete O. Clinicopathological correlates of hyperparathyroidism. Journal of clinical pathology. 2015. PMID: 26163537
  7. Christensen SE, Nissen PH, Vestergaard P. Familial hypocalciuric hypercalcaemia: a review. Current opinion in endocrinology, diabetes, and obesity. 2011. PMID: 21986511
  8. Tőke J, Czirják G, Enyedi P. Rare diseases caused by abnormal calcium sensing and signalling. Endocrine. 2021. PMID: 33528764
Educational content. This page is not medical or genetic advice, is not individually reviewed by a clinician for each reader, and should not replace a consultation with a qualified healthcare professional or genetic counsellor.